168 related articles for article (PubMed ID: 38723189)
41. Comparative clinical outcome following individualized follitropin delta dosing in Chinese women undergoing ovarian stimulation for in vitro fertilization /intracytoplasmic sperm injection.
Yang R; Zhang Y; Liang X; Song X; Wei Z; Liu J; Yang Y; Tan J; Zhang Q; Sun Y; Wang W; Qian W; Jin L; Wang S; Xu Y; Yang J; Goethberg M; Mannaerts B; Wu W; Zheng Z; Qiao J
Reprod Biol Endocrinol; 2022 Oct; 20(1):147. PubMed ID: 36195924
[TBL] [Abstract][Full Text] [Related]
42. Non-equivalence of anti-Müllerian hormone automated assays-clinical implications for use as a companion diagnostic for individualised gonadotrophin dosing.
Iliodromiti S; Salje B; Dewailly D; Fairburn C; Fanchin R; Fleming R; Li HWR; Lukaszuk K; Ng EHY; Pigny P; Tadros T; van Helden J; Weiskirchen R; Nelson SM
Hum Reprod; 2017 Aug; 32(8):1710-1715. PubMed ID: 28854583
[TBL] [Abstract][Full Text] [Related]
43. The impact of luteal serum progesterone levels on live birth rates-a prospective study of 602 IVF/ICSI cycles.
Thomsen LH; Kesmodel US; Erb K; Bungum L; Pedersen D; Hauge B; Elbæk HO; Povlsen BB; Andersen CY; Humaidan P
Hum Reprod; 2018 Aug; 33(8):1506-1516. PubMed ID: 29955789
[TBL] [Abstract][Full Text] [Related]
44. Double versus single stimulation in young low prognosis patients followed by a fresh embryo transfer: a randomized controlled trial (DUOSTIM-fresh).
Racca A; Rodriguez I; Garcia S; Arroyo G; Polyzos NP
Hum Reprod; 2024 Jun; ():. PubMed ID: 38845190
[TBL] [Abstract][Full Text] [Related]
45. Impact of endometrial preparation on early pregnancy loss and live birth rate after frozen embryo transfer: a large multicenter cohort study (14 421 frozen cycles).
Vinsonneau L; Labrosse J; Porcu-Buisson G; Chevalier N; Galey J; Ahdad N; Ayel JP; Rongières C; Bouet PE; Mathieu d'Argent E; Cédrin-Durnerin I; Pessione F; Massin N
Hum Reprod Open; 2022; 2022(2):hoac007. PubMed ID: 35274060
[TBL] [Abstract][Full Text] [Related]
46. Oral dydrogesterone versus intravaginal micronized progesterone gel for luteal phase support in IVF: a randomized clinical trial.
Griesinger G; Blockeel C; Sukhikh GT; Patki A; Dhorepatil B; Yang DZ; Chen ZJ; Kahler E; Pexman-Fieth C; Tournaye H
Hum Reprod; 2018 Dec; 33(12):2212-2221. PubMed ID: 30304457
[TBL] [Abstract][Full Text] [Related]
47. ESHRE guideline: endometriosis.
Becker CM; Bokor A; Heikinheimo O; Horne A; Jansen F; Kiesel L; King K; Kvaskoff M; Nap A; Petersen K; Saridogan E; Tomassetti C; van Hanegem N; Vulliemoz N; Vermeulen N;
Hum Reprod Open; 2022; 2022(2):hoac009. PubMed ID: 35350465
[TBL] [Abstract][Full Text] [Related]
48. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology.
Youssef MA; Van der Veen F; Al-Inany HG; Mochtar MH; Griesinger G; Nagi Mohesen M; Aboulfoutouh I; van Wely M
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD008046. PubMed ID: 25358904
[TBL] [Abstract][Full Text] [Related]
49. The ultra-long study: a randomized controlled trial evaluating long-term GnRH downregulation prior to ART in women with endometriosis.
Tomassetti C; Beukeleirs T; Conforti A; Debrock S; Peeraer K; Meuleman C; D'Hooghe T
Hum Reprod; 2021 Sep; 36(10):2676-2686. PubMed ID: 34370858
[TBL] [Abstract][Full Text] [Related]
50. Linzagolix therapy versus a placebo in patients with endometriosis-associated pain: a prospective, randomized, double-blind, Phase 3 study (EDELWEISS 3).
Donnez J; Becker C; Taylor H; Carmona Herrera F; Donnez O; Horne A; Paszkowski M; Petraglia F; Renner SP; Patel A; Boolell M; Bestel E; Dolmans MM
Hum Reprod; 2024 Jun; 39(6):1208-1221. PubMed ID: 38648863
[TBL] [Abstract][Full Text] [Related]
51. The freeze-all strategy versus agonist triggering with low-dose hCG for luteal phase support in IVF/ICSI for high responders: a randomized controlled trial.
Santos-Ribeiro S; Mackens S; Popovic-Todorovic B; Racca A; Polyzos NP; Van Landuyt L; Drakopoulos P; de Vos M; Tournaye H; Blockeel C
Hum Reprod; 2020 Dec; 35(12):2808-2818. PubMed ID: 32964939
[TBL] [Abstract][Full Text] [Related]
52. Oral dydrogesterone versus micronized vaginal progesterone for luteal phase support: a double-blind crossover study investigating pharmacokinetics and impact on the endometrium.
Loreti S; Thiele K; De Brucker M; Olsen C; Centelles-Lodeiro J; Bourgain C; Waelput W; Tournaye H; Griesinger G; Raes J; Vieira-Silva S; Arck P; Blockeel C; Mackens S
Hum Reprod; 2024 Feb; 39(2):403-412. PubMed ID: 38110714
[TBL] [Abstract][Full Text] [Related]
53. Increased versus standard gonadotrophin dosing in predicted poor responders of IVF: an open-label randomized controlled trial.
Liu X; Wen W; Wang T; Tian L; Li N; Sun T; Wang T; Zhou H; Zhang N; Qu P; Mol BW; Li W; Shi J
Hum Reprod; 2022 Jul; 37(8):1806-1815. PubMed ID: 35595197
[TBL] [Abstract][Full Text] [Related]
54. Evidence-based guideline: unexplained infertility†.
; Romualdi D; Ata B; Bhattacharya S; Bosch E; Costello M; Gersak K; Homburg R; Mincheva M; Norman RJ; Piltonen T; Dos Santos-Ribeiro S; Scicluna D; Somers S; Sunkara SK; Verhoeve HR; Le Clef N
Hum Reprod; 2023 Oct; 38(10):1881-1890. PubMed ID: 37599566
[TBL] [Abstract][Full Text] [Related]
55. Clinical outcomes from ART in predicted hyperresponders: in vitro maturation of oocytes versus conventional ovarian stimulation for IVF/ICSI.
Mostinckx L; Goyens E; Mackens S; Roelens C; Boudry L; Uvin V; Segers I; Schoemans C; Drakopoulos P; Blockeel C; De Vos M
Hum Reprod; 2024 Mar; 39(3):586-594. PubMed ID: 38177084
[TBL] [Abstract][Full Text] [Related]
56. Live birth rates after modified natural cycle compared with high-dose FSH stimulation using GnRH antagonists in poor responders.
Lainas TG; Sfontouris IA; Venetis CA; Lainas GT; Zorzovilis IZ; Tarlatzis BC; Kolibianakis EM
Hum Reprod; 2015 Oct; 30(10):2321-30. PubMed ID: 26307091
[TBL] [Abstract][Full Text] [Related]
57. Predicting the cumulative chance of live birth over multiple complete cycles of in vitro fertilization: an external validation study.
Leijdekkers JA; Eijkemans MJC; van Tilborg TC; Oudshoorn SC; McLernon DJ; Bhattacharya S; Mol BWJ; Broekmans FJM; Torrance HL;
Hum Reprod; 2018 Sep; 33(9):1684-1695. PubMed ID: 30085143
[TBL] [Abstract][Full Text] [Related]
58. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology.
Al-Inany HG; Youssef MA; Ayeleke RO; Brown J; Lam WS; Broekmans FJ
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD001750. PubMed ID: 27126581
[TBL] [Abstract][Full Text] [Related]
59. In vitro maturation without gonadotropins versus in vitro fertilization with hyperstimulation in women with polycystic ovary syndrome: a non-inferiority randomized controlled trial.
Zheng X; Guo W; Zeng L; Zheng D; Yang S; Xu Y; Wang L; Wang R; Mol BW; Li R; Qiao J
Hum Reprod; 2022 Jan; 37(2):242-253. PubMed ID: 34849920
[TBL] [Abstract][Full Text] [Related]
60. The vaginal microbiome as a predictor for outcome of in vitro fertilization with or without intracytoplasmic sperm injection: a prospective study.
Koedooder R; Singer M; Schoenmakers S; Savelkoul PHM; Morré SA; de Jonge JD; Poort L; Cuypers WJSS; Beckers NGM; Broekmans FJM; Cohlen BJ; den Hartog JE; Fleischer K; Lambalk CB; Smeenk JMJS; Budding AE; Laven JSE
Hum Reprod; 2019 Jun; 34(6):1042-1054. PubMed ID: 31119299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
